GlobeNewswire

Corvil says Transaction Data Management and Analysis Becoming Essential Skills for Optimal Execution and Improving Transparency in the Fixed Income Markets

Dela

Ahead of FIX Trading Community Americas Briefing 2018 (NYC), Corvil examines how regulatory and market pressures are catapulting technology to the forefront of fixed income

NEW YORK, April 09, 2018 (GLOBE NEWSWIRE) -- Corvil Senior Trading Strategist, Voyta Karas, has been enlisted as a moderator for today's FIX Trading Community Americas Briefing, to oversee critical discussions around the developments, challenges and opportunities arising from electronification of the fixed income markets.

Electronic trading has become an increasingly important part of the complex and highly competitive fixed income market landscape. It is driving changes in the market structure, the process of price discovery as well as how liquidity is provided.  New and existing entrants are rapidly offering more automated trading options and innovating in new methods to foster liquidity, automation and efficiency.  According to a survey by Greenwich Associates[1], almost 85 percent of surveyed investment grade investors use electronic trading, as do close to 73 percent of high-yield investors.  

Further, with trading volumes in interest rate futures overtaking those in U.S. Treasuries for the first time and looking on track for further growth[2], this creates a more complex trading environment (OTC and Exchange) that lends itself to more automated routing technologies and TCA analytics.

Greenwich Associates also investigated the state of electronic trading for corporate bonds[3], and while 76 percent of corporate bond investors say it is easy or extremely easy to execute orders up to $5 million, trades over that amount continue to prove difficult for investors to execute.  While these large trades only make up one percent of the total orders in the market on a given day, they still make up over 40 percent of the notional traded.

" Today the challenges are enormous for participants navigating the evolving roles between buy-side and sell-side players, dealing with fragmented liquidity, and doing so in a cost effective manner ," said Karas.  "The role of technology here cannot be understated.  The race to gain better access to liquidity favors those that leverage technology to gain insight from trade flows and optimize their system performance."

As a significant source of public and private financing (and by virtue, economic growth and jobs creation), regulators are flexing their muscles to improve the functioning of global bond markets. The Board of the International Organization of Securities Commissions (IOSCO), has just published recommendations[4] for improving the information on secondary corporate bond markets available to both regulators and the public.  It states that regulatory authorities should consider steps to enhance pre-trade transparency in corporate bond markets and implement regimes that require post-trade transparency.

Satisfying regulatory transparency requirements remains a pressing concern for market participants. According to a November 2017 report from Greenwich Associates[5], fixed income dealers are spending as much as $20 billion a year on RegTech to help them comply with the raft of regulations covering their trading desks.  

Corvil also sees the conversation shifting from the electronification of fixed-income to who and where to get the best data and insight sources to enable those who create liquidity and those who need it.  While MiFID II and TRACE have made the market more transparent, the next mile for market participants is to understand what this data really means to them.

Within Rates markets, the continued growth of government deficits and the need for liquidity, as the NY Fed reduces its balance sheet, are materially impacting the supply of bonds circulating and impacting liquidity.  As volatility increases within these more mature and increasingly algorithmic electronic fixed income markets, participants must gain greater insight faster about transactions and counterparties to compete. 

David Murray, Corvil Marketing and Chief Business Development Officer adds: " At the heart of improving transparency and execution performance is data analysis and accommodating new granular, voluminous, and temporary or in-transit data sources.  This is both a 'big data' and a 'continuous data' problem.  For both buy-side and sell-side participants, the ability to gain rapid, continuous insight from transaction data and use non-traditional sources to evaluate market and counterparty performance is a powerful ally.  As electronification evolves, the improved ability to measure creates new opportunities for industry benchmarks, which help define exceptional performance. Above all else, bringing "insight" to the darkness is always the greatest protection and competitive edge in changing, fast-moving markets ."

More than 290 market participant are expected to attend The FIX Americas Trading Briefing (NYC) 2018, which is hosted by Goldman Sachs. Corvil will moderate the panel sessions titled " Electronification in the Fixed Income Markets - Developments, Challenges and Opportunities ".  The highly knowledgeable and experienced panelist leading discussions includes: Bill Hayden, Managing Director, Trade Processing, Tradeweb Markets LLC;  Louis Rosato, Co-Chair Americas Regional Committee, FIX Trading Community, Director Investment Operations Group, BlackRock; Michael Babic, Head of Americas FX Electronic Distribution, Goldman Sachs and Nicola White, Managing Director and Global COO of Fixed Income Market Making, Citadel Securities.

About Corvil

Corvil is the industry leader for deriving Security, Operational, and Business intelligence from network data. As companies adopt faster and smarter machine technology, it becomes critical to tap into richer and more granular machine data sources to safeguard the transparency, performance and security of critical infrastructure and business applications. The Corvil streaming analytics platform captures, decodes, and learns from network data on the fly, transforming it into machine-time intelligence for network, IT, security and business teams to operate efficiently and securely in this new machine world. Corvil uses an open architecture to integrate the power of its network data analytics with the overall IT ecosystem providing increased automation and greater operational and business value outcomes for its users. The Corvil solution is trusted by leading financial institutions to safeguard their businesses across the globe involving 354 trillion messages with a daily transaction value in excess of $1 trillion.

Learn more about Corvil: Corvil.com | Twitter | LinkedIn

Contact information: 
Press Office at Corvil
+353 1 859 1040
pressoffice@corvil.com

Notes to the editor

[1] Source: Greenwich Associates 2017 U.S. Fixed-Income Study

[2] https://www.reuters.com/article/us-usa-bonds-futures-analysis/rate-futures-volumes-surpass-treasuries-as-market-evolves-idUSKBN1H41XH

[3] https://www.greenwich.com/fixed-income-fx-cmds/electronic-trading-matures-corporate-bonds

[4] http://www.mondovisione.com/media-and-resources/news/iosco-issues-recommendations-to-improve-regulatory-reporting-and-transparency-in/ 

[5] https://www.greenwich.com/press-release/bank-spending-regtech-fixed-income-trading-desks-tops-20-billion 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Corvil via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum